Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome — María Orietta Borghi (2020) | RDL Network
Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome
Preprint 2020 en
Authors
MB
María Orietta Borghi
AB
Asmaa Beltagy
EG
Emirena Garrafa
Abstract
1 min read
aPL show a low prevalence in COVID-19 patients and are not associated with major thrombotic events. aPL in COVID-19 patients are mainly directed against β2GPI but display an epitope specificity different from antibodies in antiphospholipid syndrome.
David M. Smadja, David M. Smadja, Pascale Gaussem, Pascale Gaussem, Carmen Roncal, Carmen Roncal, Fischer Am, Fischer Am, Joseph Emmerich, Joseph Emmerich, Luc Darnige, Luc Darnige
Discussion(0)
No comments yet. Be the first to comment.